Hypertension is an important predictor of recurrent colorectal adenoma after screening colonoscopy with adenoma polypectomy  by Lin, Chung-Chi et al.
Available online at www.sciencedirect.comScienceDirect
Journal of the Chinese Medical Association 77 (2014) 508e512
www.jcma-online.comOriginal Article
Hypertension is an important predictor of recurrent colorectal adenoma
after screening colonoscopy with adenoma polypectomy
Chung-Chi Lin a,b,d,f, Kuang-Wei Huang a,b,e, Jiing-Chyuan Luo a,b,*, Ying-Wen Wang a,b,f,
Ming-Chih Hou a,b,f, Han-Chieh Lin a,b, Fa-Yauh Lee a,b, Wan-Leong Chan a,c,f
a Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC
b Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
c Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
d Department of Medicine, Taipei Municipal Gan-Dau Hospital, Taipei, Taiwan, ROC
e Shuang-Ho Hospital and Taipei Medical University, Taipei, Taiwan, ROC
f Healthcare and Management Center, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
Received January 7, 2014; accepted March 27, 2014AbstractBackground: The predictors of recurrent colorectal adenoma have not been fully examined. This study aimed to evaluate the predictors of
recurrent colorectal adenoma after initial screening colonoscopy with adenoma polypectomy.
Methods: A retrospective cohort study was conducted at the Taipei Veterans General Hospital from 2003 to 2011. After screening, 356 patients
who had undergone two consecutive colonoscopies with colorectal adenoma polypectomy at the initial colonoscopy were enrolled. The
recurrence group was patients with recurrent colorectal adenoma at the second colonoscopy, whereas the nonrecurrence group was patients
without recurrence. Anthropometric data, biochemical tests, metabolic comorbidities, and adenoma characteristics at initial colonoscopy were
compared between the two groups. Cox proportional hazard regression analysis was conducted to identify the predictors of recurrent colorectal
adenoma.
Results: During a mean follow-up interval of 3.07 ± 1.42 years, 94 patients (26.4%) were in the recurrence group, 262 patients (73.6%) were in the
nonrecurrence group. The recurrence group was older, had a wider waist circumference, higher levels of serum alanine aminotransferase (ALT)
and triglyceride, a higher prevalence of smoking, nonalcoholic fatty liver disease, metabolic syndrome, and hypertension, and a higher occurrence
of initial multiply-located adenomas when compared with the nonrecurrence group ( p < 0.05). Cox regression analysis showed that hypertension,
smoking, higher ALT level (>40 IU/mL), and multiply-located adenomas were independent predictors for recurrent colorectal adenoma. The risk
of recurrent adenoma increased when hypertension was combined with smoking, high ALT level, or multiply-located adenomas.
Conclusion: Hypertension is an important predictor for recurrent colorectal adenoma after screening colonoscopy with polypectomy.
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Colorectal cancer (CRC) is one of the most common ma-
lignancies in the world. Although CRC's mortality in the West
is declining, it appears to have a rapidly rising trend in Asia
among both males and females.1 According to a report by the
Bureau of Health Promotion in Taiwan, CRC is the most
common cancer in Taiwan, with an age-standardized incidenceociation. All rights reserved.
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highest total lifetime health expenditure among all malig-
nancies because of its high incidence rate.2,3 Based on the
concept of the adenoma-carcinoma sequence, colorectal ade-
noma is considered a precursor of CRC. It has been believed
that screening for CRC can reduce mortality and morbidity by
detecting cancer at an earlier, curable stage and by removing
colorectal adenomas.4e6 Colonoscopic removal of colorectal
adenomas not only decreases incidence of CRC but also
significantly reduces the risk of death from CRC, as compared
with that in the general population.4,7 Therefore, several
guidelines and consensus were established for clinical CRC
screening and surveillance according to different stratified
risks.1,6,8 Current evidence supports the concept that patients
who are obese, particularly those with abdominal obesity,9
diabetes mellitus, or metabolic syndrome, are linked to insu-
lin resistance, which plays an important role in development of
CRC.10e12 Similarly, colorectal adenoma has been closely
associated with obesity, diabetes mellitus, metabolic syn-
drome, and insulin resistance in several studies.13e15 The
identification of risk patients has become important after co-
lonoscopy screening in the general population and before
surveillance in patients in whom adenoma has been previously
detected. The current study attempted to clarify the predictors
of recurrent adenoma after initial screening colonoscopy with
adenoma polypectomy.
2. Methods2.1. PatientsAsymptomatic patients who received two consecutive self-
paid health check-ups and colonoscopies with colorectal ad-
enoma polypectomy at first colonoscopy at Taipei Veterans
General Hospital, Taipei, Taiwan between January 1, 2003 and
December 31, 2010 were enrolled. There were 2255 patients
who received two consecutive check-up colonoscopies, and
there were 446 with colorectal adenoma polypectomy at first
colonoscopy. After excluding patients with a history of CRC,
inflammatory bowel disease, nonadenomatous polyp, and
long-term use of aspirin or nonsteroidal anti-inflammatory
drugs, 356 eligible patients were enrolled. This study com-
plied with the standards of the Declaration of Helsinki and
current ethical guidelines. The hospital's Institutional Review
Board approved the study (#2011-08-010IC).2.2. Anthropometric and laboratory measurementsDetailed chart review including smoking, alcohol con-
sumption, and medical and family history, were recorded.
Anthropometric measurements (i.e., body height, body weight,
waist circumference, and blood pressure) were taken by
experienced nursing staff. Waist circumference was measured
based on the modified National Cholesterol Education Program
Adult Treatment Panel III (NCEP ATP III) definition.16,17
The body mass index (BMI) was calculated as weight (kg)
divided by height (m) squared (kg/m2). Laboratory dataincluding sugar, alanine aminotransferase (ALT), gamma-
glutamyltransferase (GGT), total cholesterol, low-density li-
poprotein (LDL) cholesterol, high-density lipoprotein (HDL)
cholesterol, and triglyceride were checked. Metabolic syn-
drome was diagnosed if three or more of the following criteria
were met: (1) abdominal obesity, waist circumference 90 cm
in males and 80 cm in females; (2) high blood pressure,
130 mmHg systolic, 85 mmHg diastolic, or current medi-
cation for hypertension; (3) high serum fasting glucose,
100 mg/dL or current use of antidiabetic therapy; (4) low
HDL cholesterol level, <40 mg/dL in males and <50 mg/dL in
females; and (5) hypertriglyceridemia 150 mg/dL. Hyper-
tension was diagnosed as systolic blood pressure140 mmHg,
or diastolic blood pressure 90 mmHg18 or patients with hy-
pertension and under antihypertension medication. Liver ul-
trasound examinations were performed using the Philips HD15
ultrasound system machine (Royal Philips Electronics, North
Andover, MA, USA) by experienced radiologists. “Fatty liver”
was considered if the contrast between the liver and paren-
chyma of the right kidney was increased, whereas nonalcoholic
fatty liver disease (NAFLD) was diagnosed as the presence of
fatty liver without viral (hepatitis B or hepatitis C), autoim-
mune or other liver diseases, or heavy alcohol consumption
(>20 g/day).3 All anthropometric and laboratory data, meta-
bolic comorbidities, and the findings of screening colonoscopy
were taken at the time of the first health check-up.2.3. ColonoscopyColonoscopy was performed by experienced gastroenterol-
ogists and colorectal surgeons. The withdrawal time of colo-
noscopy was at least 6 minutes to minimize any chance of
missing lesions. Detailed colonoscopy findings, including
polyp size, number, and location and procedure of polypectomy
were recorded. A lesion above the splenic flexurewas defined as
proximal and one in the left colon including the sigmoid and
rectumwas defined as distal adenoma.3 Advanced adenomawas
defined as adenoma size >10 mm, with villous or tubule-villous
architecture, or with high-grade dysplasia.3 Multiply-located
adenomas was defined as at least two adenomas located at
different sites (including ascending colon, transverse colon,
descending colon, and sigmoid/rectum). Experienced patholo-
gists confirmed the diagnosis of adenoma by histological ex-
amination after colonoscopic polypectomy. Among the 356
eligible patients, 94 patients were classified into the recurrence
group (adenoma detected at the second colonoscopy after initial
screening colonoscopy with adenoma polypectomy), whereas
262 patients were classified into the nonrecurrence group
(absence of adenoma at the second colonoscopy after initial
screening colonoscopy with adenoma polypectomy). The ade-
noma detection rate was 19.8% for the first-time colonoscopy
and 26.4% for the second-time colonoscopy.2.4. Statistical analysisAll statistical analyses were performed using SPSS software
(version 17.0; SPSS Inc., Chicago, IL, USA). Demographic data
Table 1
Demographic characteristics between patients with or without recurrence of
colorectal adenomas.
Nonrecurrence
group
(n ¼ 262)
Recurrence
group
(n ¼ 94)
p
Male 186 (71) 76 (80) 0.076
Age (y) 54.4 ± 8.9 57.2 ± 8.9 0.010
Smoking 46 (17.6) 37 (39.4) <0.001
Body mass index (kg/m2) 24.4 ± 3.1 24.9 ± 3.2 0.144
Waist circumference (cm) 86.2 ± 8.9 88.9 ± 9.9 0.018
NAFLD 99 (37.8) 51 (54.3) 0.007
Metabolic syndrome 59 (22.5) 33 (35.9) <0.001
Hypertension 46 (17.6) 36 (38.3) <0.001
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deviation. Continuous variables were compared using the Stu-
dent t test, whereas categorical data were compared by Chi-
square test and Yates correction or Fisher's exact test, as
appropriate. Multivariate regression analysis was conducted
using Cox proportional hazard regression analysis to identify
the predictors of recurrent adenoma, including age, sex,
smoking, anthropometric data, biochemical tests, metabolic
comorbidities, and adenoma characteristics. A two-sided
p < 0.05 was considered statistically significant.
3. ResultsDiabetes 26 (9.9) 13 (13.8) 0.196
Total cholesterol (mg/dL) 206 ± 37 211 ± 39 0.2803.1. Patient characteristics
Low-density lipoprotein (mg/dL) 135 ± 33 139 ± 32 0.245
High-density lipoprotein (mg/dL) 50 ± 14 47 ± 13 0.058
Alanine aminotransferase (IU/mL) 32 ± 24 46 ± 58 0.025
Gamma-glutamyltransferase (mg/dL) 27 ± 26 35 ± 36 0.040
Triglyceride (mg/dL) 143 ± 83 172 ± 107 0.019
Advanced adenoma in initial
colonoscopya
41 (15.6) 23 (24.5) 0.062
Proximal adenoma in initial
colonoscopyb
99 (37.8) 26 (27.7) 0.080
Multiply-located adenoma in initial
colonoscopy
25 (9.5) 35 (37.2) <0.001
Data are presented as n (%) or mean ± SD.
NAFLD ¼ nonalcoholic fatty liver disease.
a Advanced adenoma: lesion >10 mm, with villous or tubulovillous archi-
tecture or high-grade dysplasia.
b Proximal adenoma: adenoma proximal to the splenic flexure.Among the 356 enrolled patients, 262 (73.6%) were male
and 94 (26.4%) female, and the mean age was 55.1 ± 9.0 years
old. Eighty-three (23.3%) patients had a history of smoking.
Eighty-two (23.0%) patients had hypertension, including 55
patients taking antihypertension medication, thirty-nine (11%)
patients had diabetes, 92 (25.8%) patients had received a
diagnosis of metabolic syndrome, and 150 (42.1%) patients
had NAFLD. The mean BMI was 24.53 ± 3.09 kg/m2. During
the initial screening colonoscopy with adenoma occurrence
and polypectomy, the most common locations of adenomas
were the sigmoid colon (n ¼ 125, 35.1%), followed by the
rectum (n ¼ 90, 25.3%) and ascending colon (n ¼ 88, 24.7%).
Sixty-four patients (18.0%) had advanced adenomas, 125
(35.1%) patients had proximal adenoma, and 60 (16.9%) pa-
tients had multiply-located adenomas.3.2. Comparison between nonrecurrence group and
recurrence groupTable 2
Independent risk factors or predictors of recurrent colorectal adenomas,
analyzed by multivariate Cox regression model.
Adjusted
HRa
95% CI p
Male 1.084 0.597e1.969 0.791
Age (y) 1.024 0.996e1.053 0.088
Smoking 2.161 1.343e3.476 0.001
NAFLD 1.260 0.813e1.954 0.301
Metabolic syndrome 0.839 0.503e1.402 0.503During a mean follow-up interval of 3.07 ± 1.42 years
between the two consecutive colonoscopic examinations, all
enrolled patients were divided into a nonrecurrence group
(n ¼ 262, 73.6%) and recurrence group (n ¼ 94, 26.4%).
Comparison between the two groups showed that the recur-
rence group was older, had a wider waist circumference,
higher serum ALT, GGT, and triglyceride, and higher preva-
lence of smoking, NAFLD, metabolic syndrome, and hyper-
tension than the nonrecurrence group ( p < 0.05, Table 1). The
recurrence group also had a higher occurrence of initial
multiply-located adenomas. However, there was no significant
difference in sex, BMI, diabetes, serum total cholesterol, LDL,
HDL, the occurrence of proximal adenoma, and advanced
adenoma between the two groups (Table 1).Hypertension 2.311 1.421e3.760 0.001
Alanine aminotransferase > 40 (IU/mL) 1.644 1.002e2.698 0.0493.3. Independent predictors for colorectal adenoma
Gamma-glutamyltransferase > 30 (mg/dL) 0.988 0.621e1.572 0.961
Advanced adenoma in initial colonoscopy 1.540 0.934e2.539 0.091
Proximal adenoma in initial colonoscopy 1.023 0.627e1.668 0.929
Multiply-located adenoma in initial
colonoscopy
3.289 2.060e5.249 <0.001
CI ¼ confidence interval; HR ¼ hazard ratio; NAFLD ¼ nonalcoholic fatty
liver disease.
a Each variable was adjusted for every other variable listed.Cox proportional hazard regression model analyses for
predictors of recurrent adenoma are shown in Table 2. Smok-
ing, hypertension, ALT >40 IU/mL, and multiply-located ad-
enomas but not metabolic syndrome were independent
predictors for developing recurrent colorectal adenoma after
initial colonoscopy with adenoma polypectomy. For 262 malepatients, smoking [hazard ratio (HR): 2.559, 95% confidence
interval (CI): 1.560e4.198], hypertension (HR: 2.372, 95% CI:
1.399e4.022), advanced adenoma (HR: 2.109, 95% CI:
1.219e3.647), and multiply-located adenomas (HR: 2.207,
95% CI: 1.306e3.731) were independent predictors for
developing recurrent colorectal adenoma after initial colonos-
copy with adenoma polypectomy. For 94 females, only ALT
>40 IU/mL (HR: 4.992, 95% CI: 1.166e21.37) and multiple-
located adenomas (HR: 37.071, 95% CI: 8.710e157.773)
Table 3
Risk for recurrent colorectal adenoma by the presence of hypertension and
other predictors.
HRa 95% CI p
Hypertension and smoking 5.013 2.372e10.597 <0.001
Hypertension and multiply-located adenoma 6.038 2.806e12.994 <0.001
Hypertension and ALT >40 IU/mL 4.182 1.939e9.018 <0.001
ALT ¼ alanine aminotransferase; CI ¼ confidence interval; HR¼ hazard ratio.
a Adjusting factors including age, sex, smoking, nonalcoholic fatty liver
disease, metabolic syndrome, hypertension, serum ALT, serum gamma-
glutamyltransferase, advanced adenoma, proximal adenoma, and multiple-
located adenoma.
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after Cox proportional hazard regression analyses.3.4. Risk of recurrent colorectal adenoma by the
presence of hypertension with other predictorsThe risk of recurrent adenoma in hypertension patients with
other predictors are shown in Table 3. By adjusting for other
confounding factors, the HR of recurrent adenoma increased
when hypertension was associated with smoking, high ALT,
and multiply-located adenomas, respectively (Table 3).
4. Discussion
About 20e50% of patients with colorectal adenomas will
experience recurrence in a 3- to 5-year period.19e21 However,
only a limited number of studies have discussed the risk fac-
tors or predictors of recurrent colorectal adenomas.22e24 In the
current study, we found that hypertension, smoking, higher
ALT (>40 IU/mL), and multiply-located adenomas were in-
dependent predictors for developing recurrent colorectal ade-
noma after initial colonoscopy with adenoma polypectomy.
Also, the risk of recurrent adenoma increased when hyper-
tension coexisted with smoking, high ALT level (>40 IU/mL),
or multiply-located adenomas, respectively.
Hypertension was found to be a predictor for colorectal
adenoma formation in previous studies,3,25 but other studies
reported conflicting findings26,27 and some did not include
hypertension as a predictor for analysis.28,29 However, studies
that evaluated the risk factors or predictors for recurrent colo-
rectal adenoma did not pay any attention to hypertension as a
potential predictor.22,23 The finding in this study that hyper-
tension rather than metabolic syndrome was a key predictor for
recurrent colorectal adenoma should remind all researchers to
pay attention to this important factor in evaluating the pre-
dictors of primary or recurrent colorectal adenoma. However,
the possible mechanisms or interactions between hypertension
and recurrent colorectal adenoma remain uncertain and need
further clarification. Whether there is a dose-response rela-
tionship between BP and recurrence of adenoma is an inter-
esting question. Because 55 of the 82 hypertension patients in
this study had taken antihypertension drugs, the baseline blood
pressure values without taking medication could not be ob-
tained exactly in two-thirds of the hypertension patients.
Therefore, we did not analyze whether a dose-responserelationship existed between blood pressure level and recur-
rence of adenoma.
Smoking has been a known risk factor of recurrent colo-
rectal adenomas,24,30 and exposure to smoking significantly
increases the prevalence of distal, tubular, larger, and multiple
adenomas.29 Several previous studies also supported that
smoking increases the size of colorectal polyps.31,32 However,
we did not observe that smoking was correlated to adenoma
number or size (data not shown). Previous studies have also
shown that smoking is an important risk factor of primary
colorectal adenoma after an initial negative screening colo-
noscopy.3 Therefore, smoking is a convenient and important
indicator for clinicians to assess primary or recurrent colo-
rectal adenomas in their daily practice.
Metabolic syndrome is composed of a cluster of cardio-
vascular risk factors including insulin resistance, dyslipidemia,
central obesity, and prehypertension. Several previous studies
have shown that metabolic syndrome is associated with
increased risk of colorectal adenoma,13,25,27,33 but others do
not support this theory.34,35 Evidence concerning the rela-
tionship between recurrent colorectal adenoma and metabolic
syndrome is relatively limited. Our study demonstrated that
metabolic syndrome was not a predictor of recurrent colorectal
adenoma by multivariate Cox regression analysis.
According to the updated guidelines for colonoscopy
surveillance after screening and polypectomy by the US Multi-
Society Task Force on Colorectal Cancer,8 the recommended
surveillance interval for multiply-located adenoma and
advanced adenoma is 3 years. About one-third of the patients
in our study had multiply-located or advanced adenoma at the
initial colonoscopy. The mean follow-up interval in this study
was 3.07 years between the two consecutive colonoscopic
examinations. Only 26.4% of patients had recurrent adenoma,
and none of them developed CRC. The updated guideline is in
line with our study findings and general clinical practice.4.1. LimitationsThe current study has several limitations that are worth
noting. First, it was a retrospective study with observations
based on patients who came in for a health check-up. Certain
selection biases indeed exist therefore caution must be exer-
cised in extrapolating the results. Second, the socioeconomic
status of our study group was relative higher in Taiwan society,
and this may be another confounding factor in data analysis.
Third, a missed polyp is inevitable for each experienced
colonoscopist during examination and decreases the accuracy
of this kind of study. However, all screening or surveillance
studies of colon adenoma-carcinoma have the same inevitable
problems. Finally, though patients taking long-term aspirin or
nonsteroidal anti-inflammatory drugs were excluded, patients
taking statins, which might be chemoprotective for colorectal
adenoma, were not excluded.
In conclusion, after adjusting for age, sex, anthropometric
data, biochemical tests, metabolic comorbidities, and adenoma
characteristics at initial colonoscopy by Cox regression anal-
ysis, hypertension was an important predictor for recurrent
512 C.-C. Lin et al. / Journal of the Chinese Medical Association 77 (2014) 508e512colorectal adenoma after screening colonoscopy with adenoma
polypectomy.
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